loading...| Preferred Name |
Certolizumab |
|
| Synonyms |
|
|
| Definitions |
A Fab fragment of a recombinant, humanized monoclonal antibody directed against the proinflammatory cytokine tumor necrosis factor-alpha (TNF-alpha), with anti-inflammatory activity. Upon administration, certolizumab binds to TNF-alpha, preventing the interaction of this cytokine with endogenous cell surface receptors, thereby rendering TNF-alpha inactive and inhibiting TNF-mediated inflammatory responses. TNF-alpha is a protein involved in inflammation, cell survival, and apoptosis. |
|
| ID |
http://purl.obolibrary.org/obo/NCIT_C97947 |
|
| code |
C97947 |
|
| Contributing_Source |
FDA |
|
| definition |
A Fab fragment of a recombinant, humanized monoclonal antibody directed against the proinflammatory cytokine tumor necrosis factor-alpha (TNF-alpha), with anti-inflammatory activity. Upon administration, certolizumab binds to TNF-alpha, preventing the interaction of this cytokine with endogenous cell surface receptors, thereby rendering TNF-alpha inactive and inhibiting TNF-mediated inflammatory responses. TNF-alpha is a protein involved in inflammation, cell survival, and apoptosis. |
|
| FDA_UNII_Code |
G6ADW90R16 |
|
| in_subset | ||
| label |
Certolizumab |
|
| NCI_Drug_Dictionary_ID |
760457 |
|
| NCI_META_CUI |
CL430555 |
|
| PDQ_Closed_Trial_Search_ID |
760457 |
|
| PDQ_Open_Trial_Search_ID |
760457 |
|
| Preferred_Name |
Certolizumab |
|
| prefixIRI |
NCIT:C97947 |
|
| prefLabel |
Certolizumab |
|
| Semantic_Type |
Pharmacologic Substance Immunologic Factor |
|
| subClassOf |